The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma
Open accessAbstract
Purpose: Persistently elevated posttreatment plasma EBV DNA is a robust predictor of relapse in nasopharyngeal carcinoma (NPC). However, assay standardization is necessary for use in biomarker-driven trials. We conducted a study to harmonize the method between four centers with expertise in EBV DNA quantitation. Experimental Design: Plasma samples of 40 patients with NPC were distributed to four centers. DNA was extracted and EBV DNA copy number was determined by real-time quantitative PCR (BamHI-W primer/probe). Centers used the same protocol but generated their own calibrators. A harmonization study was then conducted using the same calibrators and PCR master mix and validated with ten pooled samples. Results: The initial intraclass correlations (ICC) for the first 40 samples between each center and the index center were 0.62 [95% confidence interval (CI): 0.39–0.78], 0.70 (0.50–0.83), and 0.59 (0.35–0.76). The largest variability was the use of different PCR master mixes and calibrators. Standardization improved ICC to 0.83 (0.5–0.95), 0.95 (0.83–0.99) and 0.96 (0.86–0.99), respectively, for ten archival frozen samples. For fresh plasma with spiked-in EBV DNA, correlations were more than 0.99 between the centers. At 5 EBV DNA copies per reaction or above, the coefficient of variance (CV) was less than 10% for the cycle threshold (Ct) among all centers, suggesting this concentration can be reliably used as a cutoff for defining the presence of detectable EBV DNA. Conclusions: Quantitative PCR assays, even when conducted in experienced clinical labs, can yield large variability in plasma EBV DNA copy numbers without harmonization. The use of common calibrators and PCR master mix can help to reduce variability. Clin Cancer Res; 19(8); 2208–15. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sample size requirements for the design of reliability study: review and new results
Shoukri, M. M., Asyali, M. H., & Donner, A. (2004) · Statistical Methods in Medical Research · doi:10.1191/0962280204sm365ra · Cited by 459
Cited by
Chen, Y.-P., Chan, A. T. C., Le, Q.-T., Blanchard, P., Sun, Y., & Ma, J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30956-0 · Cited by 3,077
Self-citationAnalysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer
Chan, K. C. A., Woo, J. K. S., King, A., Zee, B. C. Y., Lam, W. K. J., Chan, S. L., Chu, S. W. I., Mak, C., Tse, I. O. L., Leung, S. Y. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701717 · Cited by 781
Self-citationBossi, P., Chan, A. T., Licitra, L., Trama, A., Orlandi, E., Hui, E. P., Halámková, J., Mattheis, S., Baujat, B., Hardillo, J., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.12.007 · Cited by 447
Self-citationEmerging biomarkers in head and neck cancer in the era of genomics
Kang, H., Kiess, A., & Chung, C. H. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.192 · Cited by 310
Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)
Chin, R.-I., Chen, K., Usmani, A., Chua, C., Harris, P. K., Binkley, M. S., Azad, T. D., Dudley, J. C., & Chaudhuri, A. A. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00390-5 · Cited by 191
Metadata
- Authors
- Le, Q.-T., Zhang, Q., Cao, H., Cheng, A.-J., Pinsky, B. A., Hong, R.-L., Chang, J. T., Wang, C.-W., Tsao, K.-C., Lo, Y. D., Lee, N., Ang, K. K., Chan, A. T. C., & Chan, K. C. A.
- Venue
- Clinical Cancer Research
- Published
- 2013-04-15
- Volume
- 19
- Issue
- 8
- Pages
- 2208-2215
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2138066012
- Cited by
- 179
- References
- 1
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-3702
- The paper
- Le, Q.-T., Zhang, Q., Cao, H., Cheng, A.-J., Pinsky, B. A., Hong, R.-L., Chang, J. T., Wang, C.-W., Tsao, K.-C., Lo, Y. D., Lee, N., Ang, K. K., Chan, A. T. C., & Chan, K. C. A. (2013). An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-3702
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.